As advancements in research and drug development become more complex, bioethicists are helping companies find their footing along an increasingly ambiguous path.
The priorities fall into several core themes: conduct, fiduciary standard, compliance program effectiveness, technology, operational resilience, and cybersecurity.
Recent DOJ actions, including two Michigan pharmacy schemes and a nationwide wound care provider, show how different types of misconduct can thrive within the same reimbursement system.
The Climate and Health Funders Coalition will support innovations, policies, and research on environmental hazards and climate-sensitive infectious diseases.
The House Financial Services Committee has begun to reexamine the foundations of American deposit insurance, opening a debate that blends questions of data, technology, risk, and political appetite.
A Senate agreement to restart federal operations also introduces a stringent framework for hemp-derived cannabinoid products, with significant implications for compliance teams across a $28-billion sector.
Commissioner Mark Uyeda’s remarks underscored both the depth of cooperation between the US and Japan and a widening debate over sustainability reporting standards.
There are still open questions on issues such as what guardrails (if any) an AI provider must put in place to avoid providing infringing AI-generated outputs to users.
European supervisors carried out a systematic assessment of the importance of each service provider to the financial sector, before deciding on designation.
Nikhil Rathi’s reappointment as the CEO of the FCA will run until September 2030. He tells The FT Global Banking Summit about his second term strategy.